To investigate whether circulating thyroglobulin (Tg) messenger ribonucleic acid (mRNA) and sodium/iodide symporter (NIS) mRNA transcripts in peripheral blood are valuable in the follow-up of patients with thyroid cancer, we developed highly sensitive nested Tg and NIS mRNA detection assays and compared their accuracy with serum thyroglobulin (sTg) and whole body scan with 131 I during the monitoring of 34 patients with well differentiated thyroid carcinoma who had undergone total thyroidectomy (17 of 34 also submitted to thyroid ablation with radioiodine) and were taking T 4 .
with undetectable Tg, 6 showed no cervical radioiodine uptake, and 3 presented proven metastatic disease (2 of them positive for antithyroglobulin antibodies). NIS mRNA was detected in 11 of 34 patients, but its measurement did not improve the ability to detect patients with metastases. Overall, identification of metastatic thyroid cancer was better associated with Tg mRNA than with NIS mRNA, sTg, or whole body scan (83% vs. 16.6% vs. 50% vs. 50%; P Ͻ 0.001).
These data showed that circulating Tg mRNA is not only a more sensitive marker of residual thyroid tissue or thyroid cancer than sTg, particularly in patients during T 4 therapy and with positive antithyroglobulin antibodies, but also was more sensitive than NIS mRNA in all patients. (J Clin Endocrinol Metab 85: [3623] [3624] [3625] [3626] [3627] 2000) S ERUM THYROGLOBULIN (sTg) is a very useful tumor marker to discover residual, recurring, or metastatic disease in patients with differentiated thyroid carcinoma after total thyroidectomy and ablative radioiodine (1) (2) (3) . sTg assays, however, present some technical dilemmas that decrease its clinical utility: insufficient sensitivity of many commercially available methods, "hook" effect, high interassay variation, absence of international standardization, and, mainly, interference by the presence of antithyroglobulin antibodies (TgAb), present in 15% of the patients (3) (4) (5) . Furthermore, to obtain the best possible sensitivity, many physicians recommend collection of blood after thyroid hormone removal, which causes symptomatic hypothyroidism and the possibility of tumor growth (5-7). To solve these problems, alternative methods have been devised, and some researchers have developed sensitive RT-PCR assays to amplify Tg messenger ribonucleic acid (mRNA) that were able to detect circulating thyroid cells from patients with metastatic or residual neck thyroid tissue (8 -11) .
The plasma membrane protein sodium/iodide symporter (NIS), which mediates the ability of the thyroid gland to concentrate iodine (12) , may also be used as a thyroid-specific marker. The decreased radioiodine uptake observed in some thyroid carcinomas may be due, as recently shown by several researchers, to the reduced expression and/or stability of NIS mRNA found in human thyroid tumors (13) (14) (15) . Therefore, the discordance between sTg and whole body scan (WBS) frequently observed in clinical practice may well indicate variations on the expression of genes connected to Tg and NIS.
To investigate whether Tg mRNA and NIS mRNA are valuable in monitoring patients with thyroid cancer during T 4 therapy, we developed highly sensitive Tg and NIS mRNA detection assays and compared their accuracy with sTg and WBS.
Subjects and Methods Subjects
We studied 34 patients with well differentiated thyroid carcinoma at follow-up at Hospital Sao Paulo, a teaching hospital from Universidade Federal de Sao Paulo, Brazil, and 6 normal subjects with no history or clinical evidence of thyroid disease. All 34 patients (31 women and 3 men) had been treated with near-total thyroidectomy, 17 of whom also received radioiodine ablation, according to the current clinical protocols in use at our institution. Twenty-four patients had papillary carcinoma, and 10 had follicular carcinoma, classified according to the recommendations of the WHO (16) . All patients were studied during T 4 therapy. The most recent WBS after T 4 withdrawal of each patient was used for comparison. WBS radioiodine scanning was performed 48 -72 h after a 2-to 5-mCi dose of 131 I; negative scans were those with no detectable or less than 1% of measured radioiodine uptake. Blood samples for Tg and NIS mRNA measurements by RT-PCR were obtained in combination with samples for determinations of serum TSH (Delphia immunofluorometric assay, third generation; Delphia, Turku, Finland) (17) , sTg (Brahms immunoradiometric assay, Berlin, Germany; assay with a sensitivity of 1 ng/mL) (18) , and TgAbs (19); 21 of 34 patients (61.7%) had TSH concentrations below 0.1 mU/L, 26 of 34 (76.4%) had TSH levels below 5 mU/L, and the remaining 8 patients, although clinically euthyroid, presented TSH concentrations between 6 -17 mU/L. The study was approved by the ethical committee of Hospital Sao Paulo, and written informed consent was obtained from each subject.
RNA extraction
Total RNA was isolated from 1 mL venous blood obtained from standard venipuncture and transferred immediately into sterile tubes containing 3 mL TRIzol LS reagent (Life Technologies, Inc., Gaithersburg, MD) according to the manufacturer's recommendations (20) . RNA isolated from 50 -100 mg thyroid tissue obtained from patients undergoing thyroidectomy was used as positive control. Table 1 ). Primers for ␤-actin (21), Tg (8), and NIS (22) were described previously.
RT-PCR
The cycling conditions used to generate Tg products included an initial phase of 5 min at 94 C, followed by 25 cycles of 45 s at 94 C, 90 s at 60 C, and 2 min at 72 C. After that, 1/10th of the PCR product of the first amplification was used as a template for nested PCR (23) . The reamplification was carried out in a volume of 25 L, using 66 C as the annealing temperature during 2 min for 20 more cycles.
To generate NIS products, an initial phase of 1 min at 95 C was followed by 45 cycles of 15 s at 95C, 15 s at 61 C, and 1 min at 72 C. As above, 1/10th of the PCR product was used as a template for a nested PCR (22) . The reaction was submitted to 35 PCR cycles employing the previous conditions, except for the annealing temperature of 62 C for 15 s.
RNA integrity was verified using specific primers to ␤-actin. Amplification of normal thyroid tissue was used as a positive control. Each sample was analyzed at least twice.
Analysis of amplified Tg and NIS cDNAs
After the amplification, 5 L of each PCR reaction were electrophoresed through 2% agarose gels and visualized with ethidium bromide.
To confirm the identity of nested RT-PCR-amplified Tg products, samples were digested with the restriction enzyme BglII (Life Technologies, Inc.) at 37 C overnight, analyzed on 2% agarose gels, and visualized with ethidium bromide. In addition, the specificity of each Tg and NIS amplification was verified by manual sequencing (Thermo Sequenase Radiolabeled Terminator Cycle Sequencing Kit, Amersham Pharmacia Biotech, Cleveland, OH) of the representative amplified product, using a 8% acrylamide denaturing gel in a glycerol tolerant gel buffer (Amersham Pharmacia Biotech, Arlington Heights, IL).
Statistical analysis
The association between the presence of metastases (confirmed by either fine needle aspiration cytology or surgery) and RT-PCR positivity for Tg and NIS mRNAs, sTg levels, and positive scans (thyroid bed uptake and metastases) was determined using the measurement of agreement by the STATA program (24) . P Ͻ 0.05 was considered significant.
FIG. 1. Representative nested RT-PCR products for Tg, NIS, and
␤-actin in agarose gel stained with ethidium bromide. The total RNA from the same samples was used in the RT-PCR for Tg, NIS, and ␤-actin. Patients 1 and 2 had no uptake on the most recent radioiodine scan, patients 3 and 4 had thyroid bed uptake, and patient 5 had pulmonary metastases. The expected product size for each RT-PCR product, the annealling temperature, the positions of PCR primers, and the optimized number of PCR are presented.
a Primer pairs were used for reamplification in a nested PCR.
Results

Detection of Tg and NIS mRNAs from peripheral blood by nested RT-PCRs
To detect low levels of circulating Tg and NIS mRNA transcripts, we used sensitive RT-PCR assays, optimized for both synthesis of cDNA and amplification of Tg and NIS cDNAs by nested RT-PCRs. For Tg and NIS mRNA, two rounds of amplification yielded products of 448 and 203 bp, respectively (Fig. 1) . Restriction digestion and direct nucleotide sequencing analysis indicated that 448-and 203-bp products were derived from Tg and NIS mRNAs. Synthesis of cDNA was achieved in all cases, as determined by successful amplification of ␤-actin in each sample (Fig. 1) . Furthermore, Tg and NIS mRNAs were also amplified using cDNAs prepared from all six normal subjects.
Clinical evaluation of the results of RT-PCRs for Tg and NIS mRNAs
To compare the expression of the 2 thyroid genetic markers analyzed in this study, the 34 patients were ordered according to clinical stage into 1 of 3 classes, defined by the most recent WBS or the occurrence of metastases: no uptake (n ϭ 23), thyroid bed uptake (n ϭ 8), and distant metastases (n ϭ 3). Table  2 and Fig. 2 depict the relationship between the several markers of thyroid tumors studied and the present disease status.
The upper part of Table 2 and the left portion of Fig. 2 demonstrate the results of the 23 patients who presented no residual thyroid radioiodine uptake; 22 of 23 also showed undetectable sTg measurements. However, 7 of 23 patients presented with a positive Tg mRNA assay. Of these 7 patients, 1 had detectable sTg (2.5 ng/mL); in the remaining 6 patients, we were able to observe, under careful ultrasound evaluations, the presence of suspicious metastatic cervical lymph nodes in 3 of them, confirmed by either aspirative cytology or surgery (patients 11, 12, and 22). These 3 patients were, however, negative for NIS mRNA, which may explain the lack of radioiodine uptake. The other 3 patients were positive for both Tg and NIS mRNAs, but they had undetectable sTg and suppressed serum TSH (patients 13, 14, and 15), and will need long term follow-up to demonstrate the meaning of these results. To date, they have shown no positive marker of residual or recurrent disease.
The central portion of Fig. 2 (patients 24 -31 in Table 2 ) illustrates the results of eight patients with thyroid remnants; four of them had positive Tg mRNA (three of whom also had positive NIS mRNA); two of four showed detectable and two of four showed undetectable sTg measurements. Ultrasound evaluation was negative in all of them. Despite the fact that they were receiving T 4 therapy, the serum TSH values were not completely suppressed in two patients (6.9 and 8.4 mU/L), which could stimulate Tg and NIS gene expression. These cases will also need long term follow-up to demonstrate the meaning of these results.
On the right of Fig. 2 and at the bottom of Table 2 (patients 32-34) we presented the results of patients who disclosed distant metastases (two of them with lung and one with bone metastases). Two of these patients had an aggressive form of the disease, with very elevated sTg levels and positive Tg mRNA. The remaining patient is an interesting case of a negative result for Tg and NIS mRNA. This patient, after total thyroidectomy and radioiodine ablation, started to show an elevation of sTg despite negative scans. It was then decided to treat him with an elevated dose of radioiodine, and after this dose, a new scan revealed uptake in the lung. Therefore, among patients studied while receiving thyroid hormone therapy, the sensitivity and specificity of markers to identify metastatic thyroid disease were, respectively: Tg mRNA, 83% and 71%; sTg, 50% and 89%; NIS mRNA, 16.6% and 54%; and WBS, 50% and 71%.
Discussion
Our study demonstrates that circulating Tg mRNA is a more sensitive marker of the presence of residual thyroid tissue or thyroid cancer than NIS mRNA, sTg, and WBS, particularly in patients receiving T 4 therapy and with positive anti-Tg antibodies. This observation is valuable in clinical practice, because it offers a new method capable of increasing our ability to detect residual disease without the removal of T 4 therapy and/or the use of recombinant human TSH, which is advantageous to patients. In contrast, the detection of circulating NIS mRNA in this particular setting of patients taking T 4 did not improve the ability to detect those with active disease and was not always concordant with Tg mRNA.
We have developed highly sensitive nested RT-PCRs to identify mRNA encoding Tg and NIS in blood of individuals with normal and malignant thyroid tissue. The characteristics of these assays are distinct from those of others recently reported in several aspects: the design of nucleotide primers, the conditions for synthesis of cDNA and for PCR, and the preparation of total RNA (8 -11) . Thus, our assays use nested PCR as a method to improve sensitivity, with a technique similar to that employed for other tumors, such as circulating colo-rectal, prostatic, and biliary-pancreatic tumor cells (25) (26) (27) . In fact, in the majority of our patients with positive results, we were able to detect the Tg or NIS mRNAs only after the use of a second round of PCR. We do not presume that these amplifications could be due to ectopic or illegitimate transcriptions, especially in the case of Tg mRNA, because Tg promoters show striking cell type-specific transcriptional activity and are only active in differentiated thyroid follicular cells. In addition, the molecular events involved in the differentiation of thyroid follicular cells are very specific and are dependent on the activation of a combinatorial sequence of at least three transcription factors, TTF-1, TTF-2, and PAX-8, which control their migration, growth, and differentiation (28) . Moreover, we have already had confirmation of the presence or recurrence of the tumor in three of six patients consistently negative for sTg and WBS.
In comparison with simultaneously performed NIS mRNA detection assay, sTg measurement, and WBS, the detection of Tg mRNA was more sensitive, identifying additional patients with recurrence of disease. Thus, as indicated by the results for those patients showing no radioiodine uptake, we were able to detect metastases in three patients receiving T 4 therapy, who were consistently negative for WBS and sTg measurements during follow-up. This demonstrates a superior sensitivity of Tg mRNA compared to other markers. It is important to stress that after the suspicion elicited by the positive results of Tg mRNA in these cases, the use of neck ultrasound was instrumental in discovering residual disease.
The false negative case shown on the left of Fig. 2 is in agreement with cases previously described by Tallini et al. (9) and Ringel et al. (10) of patients positive for sTg and negative for Tg mRNA, suggesting that these two tests should be used in con- junction to evaluate diverse properties of the tumors, such as the amount of circulating cancer cells released by the tumor and its potential to synthesize dissimilar proteins. Another possible explanation for this finding is the presence of polymorphisms or splice variants in the Tg molecule produced by the tumor. This would create primer mismatches impairing the appropriate annealing of primers employed in the RT-PCR. Conversely, sTg would probably be able to measure the modified protein, because the antibody used in the sTg assay would react against several Tg molecular forms.
The interpretation of negative NIS results in patients taking T 4 should be cautiously analyzed, because NIS gene expression by thyroid cells is subjected to numerous influences, mainly the induction by TSH (29) , which was suppressed in the majority of our patients. Therefore, it is difficult to differentiate whether the negative results are related to the absence of NIS expression due to genetic changes in the tumor cell, the suppressed TSH, or both. On the other hand, NIS production is not restricted to the thyroid; it is also expressed in salivary gland, mammary gland, and gastric mucosa. Therefore, positive NIS mRNA results can be derived from extrathyroid tissues (30) . Based on the false negative results shown in our studies and the possibility of false positive results due to NIS mRNA expression in nonthyroid cells, we do not suggest the use of the NIS mRNA assay for detection of circulating thyroid tumor cells.
In conclusion, the most prominent benefit of Tg mRNA detection compared to sTg measurement is the lack of interference by anti-Tg antibodies in circulation and the high sensitivity of the assay during T 4 therapy.
